Takeda Invests IDR 539 Billion to Develop Plasma-Derived Medicine Ecosystem in Indonesia

The Ministry of Investment and Downstreaming/BKPM has announced that Japanese biopharmaceutical firm Takeda will invest USD 30 million, or approximately IDR 539 billion, to develop a plasma-derived product (PODP) ecosystem in Indonesia. This initial phase of investment will span two years and focus on building a plasma bank network as the foundation for a national plasma industry.

Minister of Investment and Downstreaming Rosan Roeslani stated that the investment demonstrates growing global investor confidence in Indonesia’s investment climate, particularly in the high-tech health industry sector. “This is a strategic investment that not only brings additional capital but also opens opportunities for technology transfer, human resource development, and the creation of high-skilled jobs. The government continues to encourage investment that provides added value and strengthens national industrial capacity, so that Indonesia can become a hub for health manufacturing and innovation in the region,” he said in an official statement confirmed in Jakarta on Tuesday, 14 July 2026.

He added that Japan is one of Indonesia’s strategic investment partners. According to BKPM data, Japan was the fifth-largest investor in Indonesia in the first quarter of 2026, with an investment value reaching USD 1 billion. Meanwhile, the realisation of Japanese investment from 2021 to the first quarter of 2026 was recorded at USD 18.1 billion, with an average growth rate of 13.2 percent. This investment has absorbed approximately 299,460 workers. Rosan assessed that these achievements serve as important capital to expand investment cooperation in various priority sectors, including the health industry. As part of the project, Indonesia’s first plasma bank is targeted to begin operations by 2027, meeting global standards.